TARBOD
Live / Registered — Registered (as of 21 Jan 2025)
What this means for you
Registered since 21 Jan 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97312018
- Registration number
- 7656979
- Mark type
- Stylized text
- Filed
- 14 Mar 2022
- Published for opposition
- 03 Dec 2024
- Registered
- 21 Jan 2025
- Attorney of record
- Nicholas D. Wells
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of the pathologies of aging, neurodegenerative diseases, brain diseases, ocular diseases, skin disorders and skin conditions, kidney diseases, liver diseases, heart diseases, urology disorders, circulatory disorders, muscle diseases, pancreas diseases, digestive system diseases, lung diseases, memory loss, fatigue, eye strain, eye disease, hearing loss, hair loss, sexual disfunction and reproductive system diseases; Compound drugs and pharmaceuticals for the use in the field of oncology, immunology, inflammatory diseases, and central nervous system disorders to treat the pathologies of aging, neurodegenerative diseases, brain diseases, ocular diseases, skin disorders and skin conditions, kidney diseases, liver diseases , heart diseases, urology disorders, circulatory disorders, muscle diseases, pancreas diseases, digestive system diseases, lung diseases, memory loss, fatigue, eye strain, eye disease, hearing loss, hair loss, sexual disfunction and reproductive system diseases, by degrading disease-causing cellular proteins; Compound drugs and pharmaceuticals for the treatment of the pathologies of aging, neurodegenerative diseases, brain diseases, ocular diseases, skin disorders and skin conditions, kidney diseases, liver diseases , heart diseases, urology disorders, circulatory disorders, muscle diseases, pancreas diseases, digestive system diseases, lung diseases, memory loss, fatigue, eye strain, eye disease, hearing loss, hair loss, sexual disfunction and reproductive system diseases, by degrading disease-causing cellular proteins
Owner
- Booster Therapeutics GmbH, Berlin, DE
- Booster Therapeutics GmbH, Berlin, DE
- Booster Therapeutics GmbH, Berlin, DE
Prosecution history
- 21 Jan 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 21 Jan 2025 — REGISTERED-PRINCIPAL REGISTER
- 03 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Dec 2024 — PUBLISHED FOR OPPOSITION
- 27 Nov 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 05 Nov 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 24 Oct 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 24 Oct 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 24 Oct 2024 — ASSIGNED TO LIE
- 24 Oct 2024 — ASSIGNED TO LIE
- 19 Jul 2024 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
- 22 Dec 2023 — SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
- 14 Apr 2023 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 14 Apr 2023 — LETTER OF SUSPENSION E-MAILED
- 14 Apr 2023 — SUSPENSION LETTER WRITTEN